alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › glp1-agonists-and-ad-progression

glp1-agonists-and-ad-progression

3 studies tagged glp1-agonists-and-ad-progression, dated 2025-05-01 to 2025-12-15. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia 2025-12-15
  2. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial 2025-12-01
  3. Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias 2025-05-01

Studies

3 studies carry this tag.

Date range

2025

Top journals

  • Alzheimer s & Dementia 1
  • GeroScience 1
  • Nature Medicine 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. GeroScience 2025-12-15 Treatments

    The efficacy of acetylcholinesterase inhibitors (AChEI) and memantine (ME) in severe dementia remains uncertain, and real world data are limited.

  2. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Nature Medicine 2025-12-01 Clinical trials

    Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models.

  3. Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias

    ✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer s & Dementia 2025-05-01 How common it is

    -fold changes of 1.21, 0.57, and 4.63, respectively, compared to A-.

All topic tags with their study counts